Augmentation of cell number and LAK acti
β
Peter M. Anderson; Fritz H. Bach; Augusto C. Ochoa
π
Article
π
1988
π
Springer-Verlag
π
English
β 732 KB
A wide variety of human cancers currently have no effective treatment and are potential targets for lymphokine-activated killer (LAK) cellular immunotherapy. Relapsed acute lymphocytic leukemia (ALL) and neuroblastoma are two of the major therapeutic challenges in pediatric oncology today. However,